Bank of New York Mellon
NMRA icon

Bank of New York Mellon’s Neumora Therapeutics NMRA Stock Holding History

Bank of New York Mellon’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Buy
247,545
+208,363
+532% +$397K ﹤0.01% 3826
2026
Q1 		$76.4K Buy
39,182
+1
+0% +$3 ﹤0.01% 4119
2025
Q4 		$70.1K Buy
39,181
+19,345
+98% +$42.4K ﹤0.01% 4128
2025
Q3 		$36.1K Hold
19,836
– – ﹤0.01% 4144
2025
Q2 		$14.5K Sell
19,836
-208,019
-91% -$158K ﹤0.01% 4121
2025
Q1 		$228K Buy
227,855
+11,973
+6% +$20.5K ﹤0.01% 3831
2024
Q4 		$2.29M Sell
215,882
-549
-0.3% -$6.58K ﹤0.01% 2705
2024
Q3 		$2.86M Sell
216,431
-19,162
-8% -$224K ﹤0.01% 2580
2024
Q2 		$2.32M Buy
235,593
+194,559
+474% +$2.01M ﹤0.01% 2717
2024
Q1 		$564K Sell
41,034
-4,166
-9% -$67.4K ﹤0.01% 3448
2023
Q4 		$771K Buy
+45,200
New +$555K ﹤0.01% 3329

Other funds holding NMRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AH
Addis & Hill Wayne, Pennsylvania $181M AUM 21.74% 1-Year Est. Return

Bank of New York Mellon's NMRA Position: Q2 2026 in Review

Bank of New York Mellon increased its Neumora Therapeutics (NMRA) stake by 532% in Q2 2026, buying an estimated $397K and bringing the position to 247,545 shares worth $421K. The position accounts for ﹤0.01% of the portfolio, ranked #3826.

Bank of New York Mellon first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.86M in Q3 2024. 44 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Bank of New York Mellon held 247,545 shares of Neumora Therapeutics worth $421K as of Q2 2026.
  • Bank of New York Mellon bought 208,363 Neumora Therapeutics shares in Q2 2026, an estimated $397K.
  • Neumora Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3826 holding.
  • Bank of New York Mellon first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Bank of New York Mellon's Neumora Therapeutics position peaked at $2.86M in Q3 2024.
  • 44 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.